The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than ...

The Dexcom G7 15 Day CGM system is a wearable sensor that continuously measures glucose levels and transmits readings every 5 minutes with no fingersticks or scanning required.

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day ...

The Food and Drug Administration has cleared diabetes-management firm DexCom's new continuous glucose monitoring (CGM) system ...

The US Food and Drug Administration has cleared the latest version to last 5 days longer than previously for adult users.

Two endocrinologists who live with type 1 diabetes debate this issue at the Advanced Technologies & Treatments for Diabetes ...

Dexcom (Nadsaq:DXCM) announced today that the FDA cleared its G7 15-day continuous glucose monitoring (CGM) system.

Dexcom stock surged Thursday after the Food and Drug Administration cleared its newest diabetes device for an extended 15-day ...

Among patients with type-2 diabetes (T2D) requiring insulin therapy, automated insulin delivery (AID) resulted in a greater ...

"Prior to this study, there were concerns that continuous glucose monitors may not be as accurate during DKA because they rely on interstitial fluid, which surrounds your cells. Since patients ...

The longer wear time should improve Dexcom’s margins and help it compete with Abbott, RBC Capital Markets analyst Shagun Singh said.